472 completed, 247 unknown, 226 recruiting, 138 terminated. 612 Phase 2, 260 Phase 1, 164 Not applicable, 144 Phase 3, 15 Early Phase 1.
Follow Neoplasms, Squamous Cell: new trials by email Literature Review of Neoplasms, Squamous Cell trials Research Report on Neoplasms, Squamous Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chemo-embolization for Head and Neck Cancer Cisplatin - SCCHN, Squamous Cell Carcinoma | Phase 2 | Withdrawn | University of Alabama at Birmingham | 2027-05-01 | 2025-04-27 | |
| A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck Cemiplimab, Fianlimab, Carboplatin - Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | University of Chicago | 90 | 2027-02-07 | 2026-01-20 |
| PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC Toripalimab, Carboplatin + Paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Vanderbilt-Ingram Cancer Center | 20 | 2026-12-31 | 2026-09-23 |
| Phase 1 Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cell In Patients With Oral Premalignant Lesions TROP2 CAR/IL-15 TGFBR2 KO NK cells - Squamous Cell Carcinoma | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 36 | 2026-12-31 | 2026-06-11 |
| Screening Psychosocial Distress in Head and Neck Cancer Psychosocial distress screening using the Distress Thermometer - Head and Neck Cancer (H&N) | Not yet recruiting | Hôpital NOVO | 80 | 2026-11-30 | 2026-10-01 | |
| Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva Tisotumab Vedotin - Vulvar Carcinoma, Recurrent or Metastatic Vulvar Cancer | Phase 2 | Not yet recruiting | GOG Foundation | 28 | 2026-11-01 | 2026-06-29 |
| Basal Cell Carcinoma Chemoprevention Trial 5% Imiquimod cream, Placebo Vehicle Control Cream - Basal Cell Carcinoma | Phase 3 | Recruiting | VA Office of Research and Development | 1630 | 2026-10-06 | 2026-10-19 |
| Risk of Esophageal Cancer Returning After Immunotherapy, Chemotherapy, and Surgery Esophageal Squamous Cell Carcinoma (ESCC) | Not yet recruiting | Peking University Cancer Hospital & Institute | 100 | 2026-10-01 | 2026-09-16 | |
| Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma Sacituzumab tirumotecan, Toripalimab - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 33 | 2026-10-01 | 2026-09-16 |
| Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell Carcinoma Panitumumab-IRDye800, [18F]NOTA-ABY-030 - HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma | Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 30 | 2026-10-01 | 2026-10-19 |
| Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) Hypofractionated Stereotactic Body Radiotherapy (SBRT), Pembrolizumab, Ficerafusp alfa - Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | Washington University School of Medicine | 45 | 2026-09-30 | 2026-08-13 |
| Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC) Nivolumab-IRDye800 - HNSCC, SCC - Squamous Cell Carcinoma | Early Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 18 | 2026-09-30 | 2026-10-19 |
| A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC Tislelizumab, Oxaliplatin, Leucovorin - Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma | Phase 2 | Recruiting | BeOne Medicines | 30 | 2026-09-14 | 2026-10-14 |
| Impact of Dysport on PMFF Donor Scar Abobotulinumtoxin-A, Control- Saline injection - Skin Cancer Excision Site, Basal Cell Carcinoma | Phase 4 | Not yet recruiting | Vanderbilt University Medical Center | 50 | 2026-09-14 | 2026-08-26 |
| A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors ASP388B, Pembrolizumab, Carboplatin - Locally Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Astellas Pharma Global Development, Inc. | 392 | 2026-09-02 | 2026-09-18 |
| Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph Nodes Anlotinib, Anti-PD-1 Monoclonal Antibody - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Shanghai Chest Hospital | 75 | 2026-09-01 | 2026-09-21 |
| Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and Neck Cemiplimab, Radiation Therapy - Cutaneous Squamous Cell Carcinoma | Early Phase 1 | Recruiting | Vanderbilt-Ingram Cancer Center | 25 | 2026-09-01 | 2026-10-13 |
| Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma Standardized 3.0-T Esophageal Magnetic Resonance Imaging - Esophageal Squamous Cell Carcinoma | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 500 | 2026-09-01 | 2026-08-18 | |
| Retlirafusp Alfa Combined With Chemoradiotherapy in Unresectable ESCC Induction chemo-immunotherapy, Concurrent chemoradiotherapy (cCRT), maintenance immunotherapy - Esophageal Squamous Cell Cancer | Not applicable | Not yet recruiting | RenJi Hospital | 68 | 2026-09-01 | 2026-08-18 |
| Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma Paclitaxel polymer micelles for injection and cisplatin combined with sintilimab - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Hebei Medical University Fourth Hospital | 32 | 2026-09-01 | 2026-09-02 |
Showing 20 of 1314. Sign in to see all of them.
Carcinoma, Squamous Cell (623) · Esophageal Squamous Cell Carcinoma (622) · Head and Neck Neoplasms (204) · Squamous Cell Carcinoma of Head and Neck (198) · Esophageal Neoplasms (187) · Carcinoma, Non-Small-Cell Lung (108) · Adenocarcinoma Of Esophagus (98) · Carcinoma, Basal Cell (88) · Melanoma (84) · Skin Neoplasms (67) · Neoplasms (64) · Adenocarcinoma (56) · Neoplasm Metastasis (51) · Uterine Cervical Neoplasms (49)
Neoplasms by Histologic Type (1308) · Neoplasms, Glandular and Epithelial (1306) · Neoplasms (1250) · Carcinoma (1221) · Neoplasms by Site (1106) · Head and Neck Neoplasms (759) · Digestive System Diseases (708) · Gastrointestinal Diseases (702) · Digestive System Neoplasms (700) · Gastrointestinal Neoplasms (690) · Esophageal Diseases (651) · Carcinoma, Squamous Cell (632) · Esophageal Neoplasms (471) · Skin and Connective Tissue Diseases (178)
Cisplatin (201) · Radiotherapy (132) · Paclitaxel (111) · Fluorouracil (88) · Carboplatin (80) · pembrolizumab (79) · Cetuximab (60) · Docetaxel (58) · Drug Therapy (53) · Nivolumab (36) · Radiotherapy, Intensity-Modulated (36) · Irinotecan (33) · Radiation (33) · tislelizumab (31) · 130-nm albumin-bound paclitaxel (29)
Fudan University (36) · Sun Yat-sen University (31) · Memorial Sloan Kettering Cancer Center (28) · M.D. Anderson Cancer Center (21) · Tianjin Medical University Cancer Institute and Hospital (18) · National Cancer Institute (NCI) (17) · Peking University (17) · The First Affiliated Hospital of Zhengzhou University (14) · UNC Lineberger Comprehensive Cancer Center (14) · Merck Sharp & Dohme LLC (13) · Alpha Tau Medical LTD. (12) · Shanghai Chest Hospital (12) · Hebei Medical University Fourth Hospital (11) · National Taiwan University Hospital (11) · H. Lee Moffitt Cancer Center and Research Institute (10)
United States (494) · China (397) · France (111) · United Kingdom (72) · South Korea (66) · Spain (64) · Taiwan (64) · Canada (62) · Italy (57) · Germany (55) · Belgium (54) · Japan (41) · Australia (40) · Netherlands (36) · Israel (28)
David H. Ilson, MD, PhD (8) · Hui Liu, Professor (5) · Lin Shen, MD (5) · K Mosterd, MD, PhD (4) · Mian Xi, MD (4) · Shegan Gao, Doctor (4) · Tanyou Shan, Master (4) · Thomas Ruhstaller, MD (4) · Xiaozhi Yuan, Master (4) · Andrew Sikora, MD, PhD (3)
PMID 36990609, PMID 26254683, PMID 30089078, PMID 33373868, PMID 41309527, PMID 18309943, PMID 19465425, PMID 21684205, PMID 24982463, PMID 25057165, PMID 26808342, PMID 28742685, PMID 32017652, PMID 33538338, PMID 34160577, PMID 34454674, PMID 35440464, PMID 38710003, PMID 40373876, PMID 40467307, PMID 41531940, PMID 42580817, PMID 11208820, PMID 11391598, PMID 11870157, PMID 12049861, PMID 12167786, PMID 12771885, PMID 12885811, PMID 14673047, PMID 14759776, PMID 15061852, PMID 15151953, PMID 15533252, PMID 15753371, PMID 15800321, PMID 16129366, PMID 16235286, PMID 16467544, PMID 16515704, PMID 16601427, PMID 17259930, PMID 17327856, PMID 17921712, PMID 17960012, PMID 17960013, PMID 18270704, PMID 18474878, PMID 18574157, PMID 18640307
2019 (11), 2023 (9), 2017 (7), 2014 (6), 2015 (4), 2016 (4), 2018 (4), 2008 (3), P30CA043703 (3), U10CA032102 (3), 2009 (2), 2025 (2), P01CA021239 (2), P30CA006927 (2), P30CA008748 (2)